XML 57 R29.htm IDEA: XBRL DOCUMENT v3.25.4
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of net revenue from collaboration arrangement

Net revenue recognized under our GSK Agreements was as follows:

 

 

 

Year Ended December 31,

 

(In thousands)

 

2025

 

 

2024

 

 

2023

 

Royalties – RELVAR/BREO

 

$

204,021

 

 

$

207,925

 

 

$

208,042

 

Royalties – ANORO

 

 

46,281

 

 

 

47,631

 

 

 

44,627

 

Total royalties

 

 

250,302

 

 

 

255,556

 

 

 

252,669

 

Less: amortization of capitalized
   fees paid

 

 

(13,823

)

 

 

(13,823

)

 

 

(13,823

)

Total royalty revenue

 

$

236,479

 

 

$

241,733

 

 

$

238,846

 

Schedule of net product sales

Total net product sales were as follows:

 

 

 

Year Ended December 31,

 

(In thousands)

 

2025

 

 

2024

 

 

2023

 

GIAPREZA®

 

$

73,611

 

 

$

55,037

 

 

$

41,294

 

XACDURO®

 

 

74,393

 

 

 

21,070

 

 

 

2,003

 

XERAVA®

 

 

23,516

 

 

 

21,385

 

 

 

17,320

 

ZEVTERA®

 

 

610

 

 

 

 

 

 

 

    Total net product sales

 

$

172,130

 

 

$

97,492

 

 

$

60,617